India markets open in 8 hours 30 minutes

    +209.36 (+0.40%)
  • Nifty 50

    +69.05 (+0.44%)
  • Dow

    +169.30 (+0.48%)
  • Nasdaq

    +26.59 (+0.18%)

    -58,454.00 (-1.95%)
  • CMC Crypto 200

    +2.85 (+0.31%)
  • Hang Seng

    +841.44 (+3.30%)
  • Nikkei

    +200.76 (+0.73%)

    +0.0475 (+0.05%)

    +0.0935 (+0.09%)

    -0.0690 (-0.34%)

    -0.0007 (-0.05%)

    -0.0320 (-0.06%)

Global Biosimilars Market (2020 to 2025) - Impact Analysis of COVID-19 -

·4-min read

DUBLIN, Jun 15, 2021--(BUSINESS WIRE)--The "Global Biosimilars Market 2020-2025" report has been added to's offering.

The global biosimilars market should reach $60.1 billion by 2025 from $15.7 billion in 2020 at a compound annual growth rate (CAGR) of 30.9% for the forecast period of 2020 to 2025.

Companies Mentioned

  • 3S Bio Inc.

  • Alvotech

  • Amgen Inc.

  • Bio-Thera Solutions Ltd.

  • Biocad

  • Biocon Ltd.

  • Bioeq Gmbh

  • Biopartners Gmbh

  • Biosidus S.A.

  • Bioxpress Therapeutics S.A.

  • Blau Farmaceutica S/A

  • Boehringer Ingelheim Pharmaceuticals Inc.

  • Celltrion Inc.

  • Chong Kun Dang Pharmaceutical Corp.

  • Cinnagen

  • Cipla Ltd.

  • Coherus Biosciences Inc.

  • DM Bio Ltd.

  • Dong-A Socio Holdings

  • And Many More Companies!

Biosimilar drugs have gained immense popularity because of their impact on the lives of many patients. These drugs belong to several drug classes including hormones, interferons, growth factors (colony stimulating factors, erythropoietin) and monoclonal antibodies, among others. The use of these drugs has aided in the affordable treatment of many life-threatening diseases ranging from cancer and diabetes to chronic inflammatory diseases such as rheumatoid arthritis, psoriatic arthritis and others. The high cost of branded biologics has made biosimilars a lucrative alternative for affordable treatment. According to this report on biosimilars, the global market for biosimilars is expected to reach close to $20.8 billion by 2022, growing at a CAGR of 30.5%. Other drivers for this market include rising aging populations, patent expirations of many blockbuster drugs, and better healthcare provisions.

This updated report provides an in-depth analysis of the market for biosimilars in a global context, including market forecasts and sales through 2025. This study surveys the market for biosimilars in all the geographic regions including North America, Europe, the developed rest of the world (RoW), and emerging markets. The emerging markets include countries like India, China, Taiwan, Africa and Latin America.

The report provides an analysis of the market for biosimilars in various segments, for instance, by type, by region and by application/disease category. The report will include a detailed overview about the subject wherein the classification of biosimilar drugs along with their approval mechanisms, clinical trials and applications under review are elaborated upon.

The report also provides relevant patent analysis in both the U.S. and the European Union and comprehensive profiles of companies that lead the biosimilar drugs industry. The industry structure, focusing on the important biosimilar drug manufacturers/suppliers and their market shares and product offerings, is analyzed. This report also discusses the current market situation by elaborating upon the market drivers, restraints, challenges and opportunities. Separate chapters discuss the regulatory aspects and clinical trials. The latest news pieces including new products, new indications, mergers and acquisitions in the market are also dealt with in sufficient detail.

Excluded from this report are biobetters, generics of small molecule drugs and the biogenerics pertaining to vaccines and blood products. The different requirements for approval and bioequivalence between generics and biosimilars put them in an entirely different regime.

The Report Includes

  • 69 data tables and 73 additional tables

  • An updated review and industry insights of the global biosimilars market

  • Analyses of the global market trends, with data from 2018 to 2020, and projections of compound annual growth rates (CAGRs) through 2025

  • Highlights of the emerging market regulations, clinical trials, and new products launches; and their impact on the stakeholders in this market

  • Discussion of the biosimilars industry structure, opportunities and complexities, regulatory updates and penetration of biosimilar product classes in various regions worldwide

  • Estimation of current market size and potential growth forecast for biosimilars market, and corresponding market share analysis by product type, application/disease category and geographic region

  • A detailed review of patents issued for biosimilars by different assignee categories

  • Impact analysis of COVID-19 pandemic on the growth of biosimilars market as compared to overall pharmaceuticals industry with respect to clinical trials/approvals

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Terminology of Biosimilars

  • Definitions of Biosimilars

  • Development of a Biosimilar

  • Clone Development and Selection

  • Manufacture of a Biosimilar

  • Preclinical Studies and Validation of a Biosimilar

  • Clinical Trials

  • Approval by Regulatory Agencies

  • Pharmacovigilance/Post-Approval Monitoring

  • Biosimilars Versus Biobetters

  • Popular Types of Biosimilars

  • Recombinant Hormones

  • Recombinant Growth Factors

  • Monoclonal Antibodies (mAbs)

  • Fusion Proteins

  • Interferons

  • Low Molecular Weight Heparins (LMWHs)

Chapter 4 Market Breakdown by Type of Biosimilar

Chapter 5 Market Breakdown by Therapeutic Application

Chapter 6 Market Breakdown by Region

Chapter 7 Industry Structure

Chapter 8 Regulatory Aspects

Chapter 9 Patent Analysis

Chapter 10 Clinical Trials

Chapter 11 Analysis of Market Forces

Chapter 12 Company Profiles

Chapter 13 Appendix: Acronyms

For more information about this report visit

View source version on

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting